Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.~* Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).~* Participant is ≤12 months postpartum at screening and Day 1.~Exclusion Criteria:~* Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.~* Participant has active psychosis per investigator assessment.~* Participant has a medical history of nonfebrile seizures.~* Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.~* Participant has a history of sleep apnea.~Note: Other protocol-defined inclusion/exclusion criteria applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
- SAGE-217 50 mg (Type: EXPERIMENTAL): Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).